Board of Directors
Linda Grais, MD, JD
Director, Zosano Pharma
Linda Grais, MD, JD has served as a member of our board of directors since January 2019. Dr. Grais was previously President, Chief Executive Officer and member of the Board of Directors of Ocera Therapeutics (OCRX), a biopharmaceutical company developing novel treatments for gastrointestinal and liver diseases, from 2012 until its acquisition by Mallinckrodt in December, 2017. Dr. Grais has extensive experience in the healthcare field as a physician, biotechnology entrepreneur and investor. Previously, she was a Managing Member at InterWest Partners, a venture capital firm investing in drug development and medical device companies. Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals (SGXP), which pioneered the integration of genomics with high-throughput protein structure determination to accelerate drug discovery. SGXP went public on NASDAQ and was acquired by Eli Lilly in 2006. Prior to founding SGX, Dr. Grais worked in the corporate practice at Wilson Sonsini Goodrich & Rosati, where she represented healthcare companies in venture financings, public offerings and strategic partnerships. Dr. Grais trained in Internal Medicine and Critical Care Medicine at Yale and the University of California, San Francisco, and was an Assistant Clinical Professor of Internal Medicine and Critical Care at UCSF.
Dr. Grais received a B.A. from Yale University, Magna Cum Laude and Phi Beta Kappa, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.
Kenneth R. Greathouse
Lead Independent Director, Zosano Pharma
Kenneth R. Greathouse has served as a member of our Board of Directors since September 2017. Mr. Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business development and commercial operations. He is the co-founder of several successful drug development companies, including Manchester Pharmaceuticals which was sold to Retrophin Inc. in 2014. He began his career with Lederle Laboratories where for over 18 years he held a number of sales and marketing positions of increasing responsibility. He joined Athena Neurosciences in 1993 and continued with Elan Pharmaceuticals after the acquisition of Athena. After a two-year tenure at Boron LePore and Associates as Vice President and General Manager of Contract Sales, he joined Questcor as Senior Vice President, Commercial Operations. Since leaving Questcor, Mr. Greathouse has co-founded and served as CEO of Argent Development Group LLC, Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals LLC.
President and Chief Executive Officer, Zosano Pharma
Steven Lo is our Chief Executive Officer and member of the board of directors. Steve was previously the chief commercial officer at Puma Biotechnology where he built the commercial operations infrastructure and team to launch the company’s first product, NERLYNX®, in the United States while leading the execution of global licensing agreements for rest of world. Previously, he was senior vice president and chief commercial officer at Corcept Therapeutics. At Corcept, Mr. Lo formed the commercial organization to launch the company’s first product, Korlym®, an endocrine specialty medication for a rare orphan disease (Cushing’s syndrome) and also was responsible for the corporate strategy and development of the company’s oncology franchise. Earlier in his career, he spent 13 years at Genentech in increasingly responsible roles in market access, sales and marketing, ultimately serving as franchise head, Endocrinology. He started his career in the pharmaceutical industry at AstraZeneca after holding roles in finance and operations at Kaiser Permanente. Mr. Lo holds a master’s in health administration from the University of Southern California and a B.S. in microbiology from the University of California, Davis.
Chief Operating Officer, AVITA Medical
Kathy McGee has served as a member of our Board of Directors since May 2021. She has served as Chief Operating Officer of AVITA Medical, Inc., a publicly-held regenerative medicine company, since December 2020. Prior to AVITA, she served as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry, from 2013 to May 2021. Prior to CnA Consulting, from 2011 to 2012, Ms. McGee was the Senior Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President, Strategic Operations and General Manager from 2006 to 2011. She has also held senior operations leadership roles at Smith and Nephew plc from 2002 to 2006, a medical equipment manufacturing company and Advanced Tissue Sciences Inc. from 1992 to 2002. She received a B.S. in Chemistry and Mathematics and a Higher Diploma in Education from University College Galway (Ireland), and an M.A. in Management from Webster University.
Chief Revenue Officer, Lyra Health
Elaine Yang has served as a member of our Board of Directors since December 2021. She currently serves as chief revenue officer of Lyra Health, a company delivering comprehensive workforce mental health solutions to employers. At Lyra, Elaine manages the go-to-market teams as well as the legal, health plan billing operations and customer service teams. In her prior role as VP of operations she built and established the finance, human resources and provider network development teams. Prior to Lyra, which she joined just after its inception in 2015, Elaine built and managed finance and audit teams at Genentech before joining Facebook, both of which she joined at their early phases and experienced significant growth during her tenure. Elaine holds a BA in political science from the University of Redlands.